Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa. Kamya MR, et al. Among authors: kekitiinwa a. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93. doi: 10.1097/QAI.0b013e31814278c0. J Acquir Immune Defic Syndr. 2007. PMID: 17693883
HIV RNA suppression among HIV-infected Ugandan children with measles.
Ruel TD, Achan J, Gasasira AF, Charlebois ED, Mehbratu T, Rosenthal PJ, Dorsey G, Kamya MR, Kekitiinwa A, Wong J, Havlir DV. Ruel TD, et al. Among authors: kekitiinwa a. J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):225-7. doi: 10.1097/QAI.0b013e31816d9c86. J Acquir Immune Defic Syndr. 2008. PMID: 18520684 Free PMC article. No abstract available.
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009.
Namukwaya Z, Mudiope P, Kekitiinwa A, Musoke P, Matovu J, Kayma S, Salmond W, Bitarakwate E, Mubiru M, Maganda A, Galla M, Byamugisha J, Fowler MG. Namukwaya Z, et al. Among authors: kekitiinwa a. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):69-75. doi: 10.1097/QAI.0b013e3181fdb4a8. J Acquir Immune Defic Syndr. 2011. PMID: 21099692
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V, Kendall L, Bakeera-Kitaka S, Snowden WB, Odongo F, Thomason M, Musoke P, Adkison K, Burger D, Mugyenyi P, Kekitiinwa A, Gibb DM, Walker AS; ARROW Trial team. Musiime V, et al. Among authors: kekitiinwa a. Antivir Ther. 2010;15(8):1115-24. doi: 10.3851/IMP1695. Antivir Ther. 2010. PMID: 21149918 Clinical Trial.
Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.
Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugyenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial Team. Nahirya-Ntege P, et al. Among authors: kekitiinwa a. Pediatr Infect Dis J. 2011 Jun;30(6):535-7. doi: 10.1097/INF.0b013e3182076864. Pediatr Infect Dis J. 2011. PMID: 21164384 Clinical Trial.
121 results